FLT-3 / CD135 / FLK-2 recombinant protein

Recombinant Human FLT-3 / CD135 / FLK-2 Protein (His tag)

Cat. Num. AAA2546255

• Gene Names: FLT3; FLK2; STK1; CD135; FLK-2
• Purity: > 85 % as determined by SDS-PAGE
• Synonyms: FLT-3 / CD135 / FLK-2; Recombinant Human FLT-3 / CD135 / FLK-2 Protein (His tag); FLT3; RP11-153M24.3; CD135; FLK2; STK1; FLT-3 / CD135 / FLK-2 recombinant protein

• Host: Human Cells
• Purity/Purification: > 85 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH 7.4
• Sequence Length: 993

• Application Notes: The recombinant human FLT3 consists of 526 amino acids and has a predicted molecular mass of 59.7 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 85-95 kDa due to glycosylation.
• Predicted N Terminal: Asn 27
• Endotoxin: < 1.0 EU per mug of the protein as determined by the LAL method
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

SDS-PAGE

Related Product Information for FLT-3 / CD135 / FLK-2 recombinant protein

Background: The cluster of differentiation (CD) system is commonly used as cell markers in immunophynotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD proteins do not take part in cell signal process but have other functions such as cell adhesion. CD135, also known as FLT-3, FLK-2, is a member of the CD system. CD135 is an important cell surface marker recognized by specific sets of antibodies to identify the type s of hematopoietic (blood) progenitors in the bone marrow and it function to differentiate hematopoietic stem cells, which are CD135 negative, from multipotent progenitors, which are CD135 positive. CD135 is a receptor tyrosine kinase type III for the cytokine Flt3 ligand and activat signaling through second messengers by binding to Flt3. Signaling through CD135 is important for lymphocyte development. The encoding gene CD135 is a proto-oncogene to which mutations happened will lead to cancer such as leukemia.

Description: A DNA sequence encoding the extracellular domain of human FLT3 (NP_004110.2) (Met 1-Asn 541) was expressed, with a C-terminal polyhistidine tag.

NCBI and Uniprot Product Information

• NCBI GI #: 121114304
• NCBI GeneID: 2322
• NCBI Accession #: NP_004110.2
• NCBI GenBank Nucleotide #: NM_004119.2
• UniProt Accession #: P36888; Q13414; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0
• Molecular Weight: 108,378 Da
• NCBI Official Full Name: receptor-type tyrosine-protein kinase FLT3
• NCBI Official Synonym Full Names: fms related tyrosine kinase 3
• NCBI Official Symbol: FLT3
• NCBI Official Synonym Symbols: FLK2; STK1; CD135; FLK-2
• NCBI Protein Information: receptor-type tyrosine-protein kinase FLT3
• UniProt Protein Name: Receptor-type tyrosine-protein kinase FLT3
• UniProt Gene Name: FLT3
• UniProt Synonym Gene Names: CD135; FLK2; STK1; FLK-2; FLT-3; STK-1

NCBI Description

This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015]

Uniprot Description

FLT3: a receptor tyrosine kinase of the PDGFR family that binds the FL cytokine. FLT3 -/- mice have an impaired developmental capacity of primitive hematopoietic progenitor cells of all lineages with the greatest impact on lymphopoietic precursors. Activating mutations found in one third of cases of acute myeloid leukemia (AML), as well as in acute lymphoblastic leukemia, acute promyelocytic leukemia and myelodysplastic syndrome. Inhibitors: Sutent and PKC412.

Protein type: EC 2.7.10.1; Kinase, protein; Membrane protein, integral; Oncoprotein; PDGFR family; Protein kinase, TK; Protein kinase, tyrosine (receptor); TK group

Chromosomal Location of Human Ortholog: 13q12.2

Cellular Component: integral to plasma membrane; plasma membrane

Molecular Function: hematopoietin/interferon-class (D200-domain) cytokine receptor activity; protein binding; protein homodimerization activity; transmembrane receptor protein tyrosine kinase activity; vascular endothelial growth factor receptor activity

Biological Process: B cell differentiation; cytokine and chemokine mediated signaling pathway; hemopoiesis; leukocyte homeostasis; lymphocyte proliferation; myeloid progenitor cell differentiation; peptidyl-tyrosine phosphorylation; positive regulation of cell proliferation; positive regulation of MAP kinase activity; positive regulation of MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of tyrosine phosphorylation of STAT protein; pro-B cell differentiation; protein amino acid autophosphorylation; regulation of apoptosis; transmembrane receptor protein tyrosine kinase signaling pathway

Disease: Leukemia, Acute Lymphoblastic